Hepatitis C virus-specific directly acting antiviral drugs

Current Topics in Microbiology and Immunology

Volumn 369, Issue , 2013, Pages 289-320

  Delang, Leen ^a   Neyts, Johan ^a   Vliegen, Inge ^a   Abrignani, Sergio ^b   Neddermann, Petra ^b   De Francesco, Raffaele ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Istituto Nazionale di Genetica Molecolare   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 267; ABT 450; ACH 1625; ACH 2928; ACH 3102; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; GSK 2336805; IDX 719; MK 5172; MK 8742; NECEPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NS5B POLYMERASE; PEGINTERFERON; PPI 561; PPI 668; PROTEIN P7; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOVAPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VANIPREVIR; VEDROPREVIR; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG RESEARCH; DRUG TARGETING; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; VIRAL CLEARANCE;

HEPATITIS C VIRUS;

EID: 84876533428     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27340-7_12     Document Type: Article

References (180)

1. Afdhal N, O'Brien C, Godofsky E et al (2007) Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to pegIFN/RBV: one-year results. J Hepatol 46:S55
2. Agarwal A, Zhang B, Olek E et al (2012) Rapid and sharp decline in hepatitis C virus upon monotherapy with NS3 protease inhibitor, ACH-1625. Antivirus Therapy, in press. doi:10.3851IMP23599
3. Aghemo A, Degasperi E, Colombo M (2012) Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Digistive and liver disease, in press. doi:10.1016/j.dld.2012.05.0022
4. Assis DN, Lim JK (2012) New pharmacotherapy for hepatitis C. Clin Pharmacol Ther 92:294-3055
5. Beaulieu PL (2006) The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics. IDrugs 9:39-433
6. Beaulieu PL, Bos M, Cordingley MG et al (2012) Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV). J Med Chem 55:7650-76666
7. Belda O, Targett-Adams P (2012) Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Research, in press. doi:10.1016/j.virusres.2012.09.0077
8. Benhamou Y, Moussalli J, Ratziu V et al (2009) Results of a proof-of-concept study (C210) of telaprevir monotherapy and in combination with peginterfern alfa-2a and ribavirin in treatment- naive genotype 4 HCV patients. J Hepatol 50(1):S66
9. Berger C, Romero-Brey I, Zayas M et al (2012) HCV NS5A inhibitors alter membranous web formation and reduce PI4P induction in cells expressing HCV non-structural proteins. In: Abstracts O23 of the 19th international symposium on hepatitis C virus and related viruses, Venice, Italy, 5-9 Octo 20122
10. Berke JM, Vijgen L, Lachau-Durand S et al (2011) Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 55:3812-38200
11. Brainard DM, Anderson MS, Petry A et al (2009) Safety and antiviral activity of NS5B polymerase inhibitor MK-3281, in treatment-naïve genotype 1a, 1b and 3 HCV-infected patients. Hepatology 50:1026A-1027AA
12. Brainard DM, Petry A, Van Dyck K et al (2010) Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants in genotype 1 and 3 HCV-infected patients. Hepatology 52(1):706A-707AA
13. Bressanelli S, Tomei L, Roussel A et al (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 96:13034-130399
14. Bryson PD, Cho NJ, Einav S et al (2010) A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. Antiviral Res 87:1-88
15. Carrere-Kremer S, Montpellier-Pala C, Cocquerel L et al (2002) Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 76:3720-37300
16. Carroll SS, Olsen DB (2006) Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets 6:17-299
17. Carroll SS, Tomassini JE, Bosserman M et al (2003) Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem 278:11979-119844
18. Chang MH, Gordon LA, Fung HB (2012) Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clin Ther 34:2021-20388
19. Chatel-Chaix L, Germain MA, Gotte M, Lamarre D (2012) Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr Opin Virol 2:588-5988
20. Chen SH, Tan SL (2005) Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr Med Chem 12:2317-23422
21. Cho NJ, Dvory-Sobol H, Lee C et al (2010) Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci Transl Med 2:15-166
22. Choong IC, Cory D, Glenn JS, Yang W (2010) Methods and compositions of treating a Flaviviridae family viral infection. WO/2010/1077399
23. Conte I, Giuliano C, Ercolani C et al (2009) Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg Med Chem Lett 19:1779-17833
24. Cooper C, Lawitz EJ, Ghali P et al (2009) Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol 51:39-466
25. De Francesco R, Steinkuhler C (2000) Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr Top Microbiol Immunol 242:149-1699
26. Delang L, Froeyen M, Herdewijn P, Neyts J (2012) Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase. Antiviral Res 93:30-388
27. Deltenre P, Henrion J, Canva V et al (2004) Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 41:462-4733
28. Devogelaere B, Berke JM, Vijgen L et al (2012) TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother 56:4676-46844
29. Di Marco S, Volpari C, Tomei L et al (2005) Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 280:29765-297700
30. Dvory-Sobol H, Wong KA, Ku KS et al (2012) Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients. Antimicrob Agents Chemother 56:5289-52955
31. Edwards PD, Bernstein PR (1994) Synthetic inhibitors of elastase. Med Res Rev 14:127-1944
32. Einav S, Gerber D, Bryson PD et al (2008) Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 26:1019-10277
33. Einav S, Sobol HD, Gehrig E, Glenn JS (2010) The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis 202:65-744
34. El Hage N, Luo G (2003) Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. J Gen Virol 84:2761-27699
35. Erhardt A, Deterding K, Benhamou Y et al (2009) Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antiviral Ther 14:23-322
36. Everson GT, Sims KD, Rodriguez-Torres M et al (2012) An interferon-free, ribavirin-free 12 weeks regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naïve patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection. In: Abstracts LB-3 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9-13 Nov 20122
37. Failla C, Tomei L, De Francesco R (1994) Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 68:3753-37600
38. Failla C, Tomei L, De Francesco R (1995) An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. J Virol 69:1769-17777
39. Ferenci P (2012) Treatment of chronic hepatitis C: are interferons really necessary? Liver Int 32(1):108-1122
40. Forestier N, Zeuzem S (2012) Telaprevir for the treatment of hepatitis C. Expert Opin Pharmacother 13:593-6066
41. Forestier N, Larrey D, Guyader D et al (2011) Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 54:1130-11366
42. Foster GR, Hezode C, Bronowicki JP et al (2011a) Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141(881-889):e8811
43. Foster TL, Verow M, Wozniak AL et al (2011b) Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Hepatology 54:79-900
44. Fridell RA, Qiu D, Wang C et al (2010) Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 54:3641-36500
45. Fridell RA, Wang C, Sun JH et al (2011) Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54:1924-19355
46. Gane EJ, Roberts SK, Stedman CAM et al (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467-14755
47. Gane E, Stedman C, Hyland RH et al (2012a) Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the electron trial. In: Abstracts 229 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9-13 Nov 20122
48. Gane EJ, Stedman CA, Hyland RH et al (2012b) Electron: once daily PSI-7977 plus RBV in HCV GT1/2/3. J Hepatol 56(2):S438-S4399
49. Gao M, Nettles RE, Belema M et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-1000
50. Gopalsamy A, Aplasca A, Ciszewski G et al (2006) Design and synthesis of 3,4-dihydro-1H-[1]- benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b] benzofuran derivatives as nonnucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg Med Chem Lett 16:457-4600
51. Goudreau N, Llinas-Brunet M (2005) The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin Investig Drugs 14:1129-11444
52. Gouttenoire J, Penin F, Moradpour D (2010) Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Rev Med Virol 20:117-1299
53. Gray F, Amphlett E, Bright H et al (2007) GSK625433; a novel and highly potent inhibitor of the HCVNS5B polymerase. J Hepatol 46:S2255
54. Griffin SD, Beales LP, Clarke DS et al (2003) The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadine. FEBS Lett 535:34-388
55. Griffin S, StGelais C, Owsianka AM et al (2008) Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology 48:1779-17900
56. Gu B, Johnston VK, Gutshall LL et al (2003) Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J Biol Chem 278:16602-166077
57. Hebner CM, Han B, Brendza KM et al (2012) The HCV Non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. Plos One 7:e391633
58. Hong Z, Cameron CE, Walker MP et al (2001) A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 285:6-111
59. Howe AY, Bloom J, Baldick CJ et al (2004) Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 48:4813-48211
60. Howe AY, Cheng H, Thompson I et al (2006) Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor. Antimicrob Agents Chemother 50:4103-41133
61. Howe AY, Cheng H, Johann S et al (2008) Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother 52:3327-33388
62. Huang Y, Staschke K, De Francesco R, Tan SL (2007) Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology 364:1-99
63. Huang M, Podos S, Patel D et al (2010) ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants. Hepatology 52(S1):1204AA
64. Jacobson I, Pockros P, Lalezari J et al (2009) Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. J Hepatol 50:S382-S3833
65. Kazmierski WM, Hamatake R, Duan M et al (2012) Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants. J Med Chem 55:3021-30266
66. Khoury G, Ewart G, Luscombe C et al (2010) Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother 54:835-8455
67. Kieffer TL, Sarrazin C, Miller JS et al (2007) Telaprevir and pegylated interferon-alpha- 2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631-6399
68. Kim JL, Morgenstern KA, Lin C et al (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-3555
69. Kneteman NM, Howe AYM, Gao TJ et al (2009) HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49:745-7522
70. Kowdley KV, Lawitz E, Crespo I et al (2012a) Atomic: 97% RVR for PSI-7977 + PEG/RBV X 12 weeks regimen in HCV GT1: an end to response-guided therapy? J Hepatol 56(2):S11
71. Kowdley KV, Lawitz E, Poordad F et al (2012b) A 12 weeks interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype1 infection. In: Abstracts LB-1 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9-13 Nov 20122
72. Kukolj G, McGibbon GA, McKercher G et al (2005) Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 280:39260-392677
73. Kwo PY, Lawitz EJ, McCone J et al (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-7166
74. Lagace L, White PW, Bousquet C et al (2012) In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother 56:569-5722
75. Lam AM, Espiritu C, Bansal S et al (2011a) Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol 85:12334-123422
76. Lam AM, Espiritu C, Murakami E et al (2011b) Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of {beta}-D-2′-deoxy-2′-{alpha}-fluoro- 2′-{beta}-C- Methylguanosine. Antimicrob Agents Chemother 55:2566-25755
77. Lam AM, Espiritu C, Bansal S et al (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359-33688
78. Lamarre D, Anderson PC, Bailey M et al (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-1899
79. Larrey DG, Benhamou Y, Lohse AW et al (2009) Bi 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. Hepatology 50:1044A
80. Larrey D, Lohse AW, de Ledinghen V et al (2012) Rapid and strong antiviral activity of the nonnucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 57:39-466
81. Lawitz E, Nguyen T, Younes Z et al (2006) Valopicitabine (NM283) plus PEG-interferon in treatment- naive hepatitis C patients with HCV genotype-1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatology 44:223AA
82. Lawitz E, Rodriguez-Torres M, DeMico M et al (2009) Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 50:S3844
83. Lawitz E, Gaultier I, Poordad F et al (2010a) 4 weeks virologic response and safety of ABT- 450 given with low-dose ritonavir (ABT-450r) in combination with pegylated interferon alfa 2a and ribavirin after 3 days monotherapy in HCV-infected treatment-naive subjects. Hepatology 52(1):878A-979AA
84. Lawitz E, Rodriguez-Torres M, Rustgi V et al (2010b) Safety and antiviral activity of ANA598 in combination with pegylated IFN alpha 2a plus ribavirin in treatment-naïve genotype-1 chronic HCV patients. Hepatology 52:334A-335AA
85. Lawitz E, Rodriguez-Torres M, Denning JM et al (2011) Once dialy dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA > LOD at day 14: first purine/pyrimidine clinical combination data (the nuclear study). J Hepatol 54:S5433
86. Lawitz EJ, Gruener D, Hill JM et al (2012) A phase 1, randomized, placebo-controlled, 3 days, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57:24-311
87. Le Pogam S, Jiang WR, Leveque V et al (2006a) In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349-3599
88. Le Pogam S, Kang H, Harris SF et al (2006b) Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 80:6146-61544
89. Le Pogam S, Seshaadri A, Ewing A et al (2010) RG7128 alone or in combination with pegylated interferon-alpha 2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 202:1510-15199
90. Lee LY, Tong CY, Wong T, Wilkinson M (2012) New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 66:342-3555
91. Lemm JA, O'Boyle D 2nd, Liu M et al (2010) Identification of hepatitis C virus NS5A inhibitors. J Virol 84:482-4911
92. Lemm JA, Leet JE, O'Boyle DR 2nd et al (2011) Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrob Agents Chemother 55:3795-38022
93. Lenz O, Verbinnen T, Lin TI et al (2010) In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54:1878-18877
94. Lesburg CA, Cable MB, Ferrari E et al (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6:937-9433
95. Li H, Tatlock J, Linton A et al (2009) Discovery of (R)-6-Cyclopentyl-6- (2-(2,6-diethylpyridin- 4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a] pyrimidin-2-yl)methyl)-4-hydroxy- 5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 52:1255-12588
96. Lin C, Thomson JA, Rice CM (1995) A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J Virol 69:4373-43800
97. Lin C, Lin K, Luong YP et al (2004) In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 279:17508-175144
98. Lin C, Kwong AD, Perni RB (2006) Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3-4A serine protease. Infect Disord Drug Targets 6:3-166
99. Lin TI, Lenz O, Fanning G et al (2009) In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 53:1377-13855
100. Liu R, Kong R, Mann P et al (2012) In vitro resistance analysis of HCV NS5A inhibitor MK-8742 demonstrates increased potency against clinical resistance variants ans higher resistance barrier. J Hepatol 56(2):S334-S3355
101. Liverton NJ, Carroll SS, Dimuzio J et al (2010) MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 54:305-3111
102. Love RA, Parge HE, Wickersham JA et al (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331-3422
103. Love RA, Brodsky O, Hickey MJ et al (2009) Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 83:4395-44033
104. Ludmerer SW, Graham DJ, Boots E et al (2005) Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 49:2059-20699
105. Luik P, Chew C, Aittoniemi J et al (2009) The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci USA 106:12712-127166
106. Luscombe CA, Huang Z, Murray MG et al (2010) A novel hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res 86:144-1533
107. Ma H, Jiang WR, Robledo N et al (2007) Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-deoxy- 2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 282:29812-298200
108. Macdonald A, Harris M (2004) Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85:2485-25022
109. Manns MP, Bourliere M, Benhamou Y et al (2011) Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 54:1114-11222
110. May MM, Brohm D, Harrenga A et al (2012) Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors. Antiviral Res 95:182-1911
111. McCown MF, Rajyaguru S, Le Pogam S et al (2008) The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 52:1604-16122
112. McGuigan C, Madela K, Aljarah M et al (2010) Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett 20:4850-48544
113. McPhee F, Friborg J, Levine S et al (2012a) Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 56:3670-36811
114. McPhee F, Sheaffer AK, Friborg J et al (2012b) Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 56:5387-53966
115. Membreno FE, Lawitz EJ (2011) The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis 15:611-6266
116. Migliaccio G, Tomassini JE, Carroll SS et al (2003) Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278:49164-491700
117. Moreno C, Berg T, Tanwandee T et al (2012) Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 56:1247-12533
118. Murakami E, Bao H, Ramesh M et al (2007) Mechanism of activation of beta-D-2′-deoxy-2′- fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 51:503-5099
119. Murakami E, Niu CR, Bao HY et al (2008) The mechanism of action of beta-D-2′-deoxy-2′- fluoro-2′-C-methylcytidme involves a second metabolic pathway leading to beta-D-2′- deoxy-2-fluoro-2′-C- methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 52:458-4644
120. Narjes F, Crescenzi B, Ferrara M et al (2011) Discovery of (7R)-14-cyclohexyl-7-{[2- (dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H- indolo[1,2-e][1,5]benzoxazocine- 11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem 54:289-3011
121. Nelson DR, Gane EJ, Jacobson IM et al (2011) VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: zenith study, SVR12 interim analysis. Hepatology 54:1435AA
122. Nguyen TT, Gates AT, Gutshall LL et al (2003) Resistance profile of a hepatitis C virus RNAdependent RNA polymerase benzothiadiazine inhibitor. Antimicrob Agents Chemother 47:3525-35300
123. Olsen DB, Eldrup AB, Bartholomew L et al (2004) A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 48:3944-39533
124. Pasquinelli C, McPhee F, Eley T et al (2012) Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 56:1838-18444
125. Pauwels F, Mostmans W, Quirynen LMM et al (2007) Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J Virol 81:6909-69199
126. Pawlotsky JM, Najera I, Jacobson I (2012) Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther 17:411-4233
127. Pessoa MG, Cheinquer H, Almeida PR et al (2012) Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial. Ann Hepatol 11:52-611
128. Pierra C, Amador A, Benzaria S et al (2006) Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 49:6614-66200
129. Pol S, Ghalib RH, Rustgi VK et al (2012) Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 12:671-6777
130. Poordad F, Lawitz E, Kowdley KV et al (2012a) 12 weeks interferon-free regimen of ABT- 450/R + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol 56(2):S549-S5500
131. Poordad F, Lawitz E, Kowdley KV et al (2012b) 12 weeks interferon-free regimen of ABT- 450/R + ABT-333 + ribavirin achieved svr12 in more than 90% of treatment-naive HCV genotype- 1-infected subjects and 47% of previous non-responders. J Hepatol 56:S549-S5500
132. Qiu D, Lemm JA, O'Boyle DR 2nd et al (2011) The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol 92:2502-25111
133. Rai R, Deval J (2011) New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res 90:93-1011
134. Reddy MB, Chen Y, Haznedar JO et al (2012) Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study. Clin Pharmacokinet 51:457-4655
135. Reesink HW, Fanning GC, Farha KA et al (2010) Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138:913-9211
136. Reghellin V, Fenu S, Bianco A et al (2012) HCV NS5A inhibitor BMS-790052 exerts its antiviral effects by reducing phosphatidylinositol 4-phosphate levels in the virus-induced membranous web. In: Abstracts LB-9 of the 19th international symposium on hepatitis C virus and related viruses, Venice, Italy, 5-9 Octo 20122
137. Reiss S, Rebhan I, Backes P et al (2011) Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-455
138. Rodriguez-Torres M, Lawitz E, Conway B et al (2010) Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV-infected patients. J Hepatol 52:S144
139. Rodriguez-Torres M, Lawitz E, Hazan L et al (2011) Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7 days of oral therapy in naive genotype-1 chronic HCV patients. Hepatology 54:535AA
140. Romano KP, Ali A, Aydin C et al (2012) The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. Plos Pathog 8:e10028322
141. Sakai A, St Claire MS, Faulk K et al (2003) The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA 100:11646-116511
142. Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-4622
143. Sarrazin C, Kieffer TL, Bartels D et al (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-17777
144. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56(1):S88-S1000
145. Schaefer EA, Chung RT (2012) Anti-hepatitis C virus drugs in development. Gastroenterology 142(1340-1350):e13411
146. Chechter I, Berger A (1967) On the size of the active site in proteases. I Papain Biochem Biophys Res Commun 27:157-1622
147. Seiwert SD, Andrews SW, Jiang Y et al (2008) Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 52:4432-44411
148. Sheng XC, Appleby T, Butler T et al (2012a) Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett 22:2629-26344
149. Sheng XC, Casarez A, Cai R et al (2012b) Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorg Med Chem Lett 22:1394-13966
150. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-5677
151. Shi ST, Herlihy KJ, Graham JP et al (2009) Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 53:2544-25522
152. Slater MJ, Amphlett EM, Andrews DM et al (2007) Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. J Med Chem 50:897-9000
153. Smith JP (1997) Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 42:1681-16877
154. Steinmann E, Penin F, Kallis S et al (2007a) Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. Plos Pathog 3:962-9711
155. Steinmann E, Whitfield T, Kallis S et al (2007b) Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 46:330-3388
156. Stuyver LJ, McBrayer TR, Tharnish PM et al (2006) Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C- methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 17:79-877
157. Sulkowski M, Rodriguez-Torres M, Lawitz E et al (2012a) High sustained virologic response rate in treatment-naïve HCV genotype 1a and 1b patients treated for 12 weeks with an interferon- free all-oral quad regimen: interim results. J Hepatol 56:S5600
158. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al (2012b) High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV genotype 1, 2, or 3. In: Abstracts LB-2 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9-13 Nov 20122
159. Summa V, Ludmerer SW, McCauley JA et al (2012) MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161-41677
160. Susser S, Welsch C, Wang Y et al (2009) Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709-17188
161. Tanwandee T, Luscombe CA, Ewart G et al (2011) Antiviral activity and tolerability of BIT2255 plus pegylated interferon alpha 2a or 2b and weight-based ribavirin for 28 days in HCV treatment-naïve monoinfected patients. Glob Antiviral J 7(1):64 HEP DART 20111
162. Targett-Adams P, Graham EJ, Middleton J et al (2011) Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol 85:6353-63688
163. Tellinghuisen TL, Marcotrigiano J, Rice CM (2005) Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-3799
164. Thompson P, Patel R, Steffy K, Appleman J (2009) Preclinical studies of ANA598 combined with other Anti-HCV agents demonstrate potential of combination treatment. J Hepatol 50:S377
165. Tomei L, Failla C, Santolini E et al (1993) NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67:4017-40266
166. Tomei L, Altamura S, Bartholomew L et al (2003) Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 77:13225-132311
167. Tomei L, Altamura S, Bartholomew L et al (2004) Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol 78:938-9466
168. Trozzi C, Bartholomew L, Ceccacci A et al (2003) In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 77:3669-36799
169. Vernachio JH, Bleiman B, Bryant KD et al (2011) INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 55:1843-18511
170. von Wagner M, Hofmann WP, Teuber G et al (2008) Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology 48:1404-14111
171. Wagaw S, Ravn M, Engstrom K et al (2009) Process for making macrocyclic oximyl hepatitis C protease inhibitors. WO/2009/0737800
172. Wagner F, Thompson R, Kantaridis C et al (2011) Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 54:50-599
173. Wang M, Ng KK, Cherney MM et al (2003) Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 278:9489-94955
174. White PW, Llinas-Brunet M, Amad M et al (2010) Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 54:4611-46188
175. Yan Y, Li Y, Munshi S et al (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 7:837-8477
176. Yang G, Wiles J, Patel D et al (2012) Preclinical characteristics of of ACH-3102: a novel HCV NS5A inhibitor with imporved potency against genotype-1a virus and variants resistant to 1st generation of NS5A inhibitors. J Hepatol 56(2):S3300
177. Yi G, Deval J, Fan B et al (2012) Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother 56:830-8377
178. Zeuzem S, Buggisch P, Agarwal K et al (2012a) The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55:749-7588
179. Zeuzem S, Soriano A, Asselah T et al (2012b) Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127 ribavirin (R): final results of SOUND-C2 and predictors of response. In: Abstracts 232 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9-13 Nov 20122
180. Zhou XJ, Pietropaolo K, Chen J et al (2011) Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother 55:76-811